Six years after withdrawing IPO, Abpro takes SPAC route to Nasdaq — with plans to take HER2 bispecific to clinic
Abpro, an antibody maker working on T cell engagers that target HER2+ cancer types, is going public through merging with a SPAC company dubbed Atlantic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
